episode 922: TWiV clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses monkeypox infection in humans across 16 countries, pregnancy outcomes after SARS-CoV-2 infection by trimester, vaccination intent and belief, antiviral drug treatment for non-severe disease, the association of smoking with infected hospitalized patients, the association of Paxlovid on negative conversion rates among high-risk patients with COVID-19, safety and efficacy of Molnupiravir, usage of enoxaparin for primary thromboprophylaxis, statin and aspirin as therapy in infected patients, post-COVID-19 conditions among children 90 days after SARS-CoV-2 Infection, and symptoms and risk factors for long COVID in non-hospitalized adults.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Monkeypox infection in humans (NEJM)
- Pregnancy outcomes after infection (PLOS ONE)
- Vaccination intent and belief (Emerging Infectious Diseases)
- Antiviral drug treatment for non-severe disease (CMAJ)
- Smoking association with infected hospitalized patients (PLOS ONE)
- Impact of Paxlovid on negative conversion rates (CID)
- PAXLOVID patient eligibility screening checklist (FDA)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Safety and efficacy of Molnupiravir (Journal of Medical Virology)
- Enoxaparin for primary thromboprophylaxis (OVID)
- Statin and aspirin as therapy in infected patients (BMC)
- Post-infection conditions among children (JAMA)
- Symptoms and risk factors for long-term effects (Nature Medicine)
- Contribute to FIMRC fundraiser at PWB
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 922
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv